Last reviewed · How we verify
Anticoagulant Therapy
Anticoagulant therapy prevents blood clot formation by inhibiting coagulation cascade factors or platelet aggregation.
Anticoagulant therapy prevents blood clot formation by inhibiting coagulation cascade factors or platelet aggregation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Acute coronary syndrome.
At a glance
| Generic name | Anticoagulant Therapy |
|---|---|
| Also known as | Еnoxaparin |
| Sponsor | Shenyang Northern Hospital |
| Drug class | Anticoagulant |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Anticoagulants work through multiple mechanisms depending on the specific agent: some inhibit vitamin K-dependent factors (warfarin), others directly inhibit thrombin or Factor Xa (direct oral anticoagulants), and some enhance natural anticoagulants like antithrombin (heparins). These mechanisms collectively reduce the risk of thromboembolism by preventing pathological clot formation while maintaining hemostasis.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) prevention and treatment
- Acute coronary syndrome
- Mechanical heart valve thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants) (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Management of Anticoagulant Therapy Monitored by an Implantable Device With Telecardiology in Patients With Acute Coronary Syndrome Associated With de Novo Atrial Fibrillation Arrhythmia (PHASE4)
- Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding (NA)
- A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticoagulant Therapy CI brief — competitive landscape report
- Anticoagulant Therapy updates RSS · CI watch RSS
- Shenyang Northern Hospital portfolio CI